Should I buy Syncom Formulations stock in India in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Syncom Formulations for over three years. Every month, over a million users in India trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Syncom Formulations.

What is Syncom Formulations?

How much is Syncom Formulations stock?

The price of Syncom Formulations stock is rising this week.

The current stock price stands at ₹19.29, up 1.85% over the last 24 hours and 0.31% for the week.

Syncom Formulations has a market capitalization of ₹1,813 crores and an average three-month trading volume of 3.70 million shares.

The stock trades at a P/E Ratio of 36.40, and currently does not pay a dividend (0.00% yield).

Its beta is 1.16, indicating higher price volatility compared to the broader market.

This dynamic reflects strong growth potential but also suggests investors should expect some price swings.

Our Full Analysis of the Syncom Formulations Stock

We have thoroughly reviewed Syncom Formulations’s latest financial results and analyzed its share price performance over the past three years. Drawing upon a combination of primary financial indicators, technical signals, real-time market data, and competitor benchmarks—incorporated into our proprietary algorithms—this analysis aims to provide a comprehensive perspective for investors. So, why might Syncom Formulations stock once again become a strategic entry point into the Indian pharmaceutical sector in 2025?

Recent performance and market context

The stock price of Syncom Formulations is currently trading at ₹19.29, having delivered a robust 1-year performance with a return exceeding 52%, including a steady 0.3% gain this week and a 1.85% rise over the last 24 hours. This resilient price momentum reflects substantial earnings growth, underpinned by an impressive 99.6% year-on-year revenue jump in the latest quarter. Major positive events—such as the successful commissioning of a solar power plant and strong export-led growth—have further strengthened the company’s reputation in both domestic and international markets. The Indian pharmaceutical sector, characterized by dynamic growth and resilient consumption patterns, offers a favourable macroeconomic context for well-positioned players like Syncom Formulations, amplified by rising global demand for generics and specialty formulations.

Technical analysis

Technical indicators underscore a predominantly bullish undertone for Syncom Formulations. As of early July 2025, the 14-day Relative Strength Index (RSI) at 46.0 suggests a neutral-to-positive setup, neither overbought nor oversold. The stock trades above its 50-day and 100-day moving averages, signalling robust medium-term support, with major technical support at ₹18.20 and resistance at ₹20.52. Although the MACD slightly lags below the signal line, the prevailing structure—with the stock above 6 out of 8 key moving averages—reflects a clear bias towards an emerging medium-term trend reversal. This technical resilience, especially the stock’s ability to defend support levels and recover rapidly, is a bullish sign for upcoming quarters.

Fundamental analysis

Fundamentally, Syncom Formulations stands out for its powerful operational momentum. Revenues surged 76% year-on-year to ₹465.01 crores in FY2025, while net profit nearly doubled, climbing 95% to ₹49.43 crores. The company’s EBITDA and net margin improvements are supported by remarkable export growth—now comprising 86% of total revenue and up 88% year-on-year—which attests to the management’s disciplined execution of global strategy. Despite its Price/Earnings Ratio of 36.40 sitting above the sector average, this is justified by the acceleration of earnings, expanding international footprint, and strong visibility on future growth. The company’s robust innovation pipeline, highlighted by more than 500 pharmaceutical formulations spanning tablets, capsules, liquids, and injectables, cements its market position and provides the foundation for sustained share gains. The absence of dividend payments, while notable, supports capital redeployment towards business expansion and R&D, further fuelling growth prospects.

Volume and liquidity

Syncom Formulations enjoys a solid trading base, with a three-month average daily volume of 3.7 million shares, illustrating consistent market engagement by both institutional and retail investors. This healthy liquidity facilitates efficient price discovery, narrow bid-ask spreads, and positions the stock for swift valuation adjustments as new information emerges. The shareholding structure, balanced between promoters (50.57%) and the wider public (49.32%), supports steady float levels and a dynamic market environment.

Catalysts and positive outlook

Looking ahead, Syncom Formulations is poised to capitalize on several potent catalysts:

• The successful deployment of a green energy (solar) initiative at its Pithampur factory demonstrates leadership in environmental stewardship and operational cost savings, enhancing ESG credentials.
• International expansion continues apace, with presence now in over 25 countries and more than 400 products registered—a testimony to the company’s agility and regulatory expertise in global markets.
• The growing contribution of export sales and the company’s highly scalable model ensure that incremental revenues feed directly into margins, allowing earnings leverage.
• Strategic investments in manufacturing, automation, and digital marketing support both top-line growth and operational efficiencies.
• A dedicated domestic sales force (about 1,000 representatives) enhances brand penetration and market share in one of the world’s fastest-growing pharmaceutical markets.

Industry tailwinds—in particular, the rising global demand for generics, government incentives for pharma innovation, and increasing healthcare expenditure in both developed and emerging markets—compound these company-specific drivers, setting the stage for outsized performance.

Investment strategies

For investors seeking optimal entry, several factors converge to suggest a timely opportunity:

• In the short term, the recent price stabilization above key support levels and healthy trading momentum offer a compelling technical base for tactical positioning.
• Investors with a medium-term horizon can benefit from the company’s ongoing export-driven growth and the likely rerating as fundamental metrics continue to outpace sector averages.
• For long-term participants, Syncom Formulations’s scalable business model, diversified revenue streams, and proven ability to innovate underpin a case for compounding returns as the company expands its global presence.

Ideally, accumulation on technical pullbacks toward the ₹18.20 support, or ahead of quarterly earnings releases—typically accompanied by positive surprises—could optimize risk-reward. With consensus earnings forecasts trending higher and a robust pipeline of potential catalysts, Syncom Formulations may be entering a new, sustainable growth phase.

Is it the right time to buy Syncom Formulations?

All key data points—exceptional revenue and profit growth, geographic and product diversification, strategic expansion, and strong liquidity—reinforce the positive case for Syncom Formulations. The blend of a high-growth story, resilient operating metrics, and proactive ESG initiatives means the fundamentals justify renewed investor interest, even at elevated valuations. While shares do not currently offer a dividend, this choice highlights management’s clear focus on reinvestment and expansion, uniquely positioning the company among listed Indian pharma peers.

In summary, Syncom Formulations presents a rare combination of sustained operational outperformance, emerging technical strength, scalable growth levers, and multiple upcoming catalysts. For investors who seek exposure to high-potential Indian healthcare innovators, current trading levels seem to represent an excellent opportunity to participate in the next stage of this company’s bullish journey. The stock’s improving technical landscape and outstanding fundamental advances make it a prime candidate for renewed accumulation, with upside potential that is both convincing and well supported by recent achievements.

How to buy Syncom Formulations stock in India

Buying Syncom Formulations stock online is both simple and secure when you use a regulated broker approved by Indian authorities. Most investors choose between two main methods: purchasing shares directly (spot buying) or trading Contracts for Difference (CFDs), which allow you to speculate on the stock’s price movements with leverage. Both approaches can be accessed through reliable trading platforms in India. To make the best choice, it’s essential to understand the differences, benefits, and costs of each method; you’ll find a broker comparison further down the page.

Spot buying

When you buy Syncom Formulations stock for cash, you become a direct shareholder in the company. This method involves paying the full share price up front and typically includes a fixed commission per order—often around ₹100 to ₹300 on Indian platforms.

Gain scenario

If the Syncom Formulations share price is ₹19.29, you can buy around 51 shares with a ₹1,000 stake, including a brokerage fee of about ₹100.

If the share price rises by 10%, your shares are now worth ₹1,100.

Result: +₹100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFDs, or Contracts for Difference, let you trade the price movements of Syncom Formulations shares without owning the actual stock. CFD trading involves costs such as the spread—the small difference between buy and sell price—and potential overnight financing if you hold positions for more than a day. You can also apply leverage to amplify your exposure, but this increases both potential gains and losses.

CFD Gain Scenario with Leverage

You open a CFD position on Syncom Formulations shares with 5x leverage and a ₹1,000 stake. This gives you a market exposure of ₹5,000.

Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +₹400 gain, on a bet of ₹1,000 (excluding fees).

Final advice

Before investing, always compare brokers’ fees, trading conditions, and available features to suit your needs—remember, you’ll find a detailed comparison further down the page. Your choice between spot buying and CFD trading should align with your objectives, risk tolerance, and investment horizon: both methods can be accessible and efficient when you choose the right platform.

Our 7 tips for buying Syncom Formulations stock

The latest news about Syncom Formulations

Syncom Formulations stock rises 1.85% in the last trading session, continuing a positive short-term trend. The share price increased to ₹19.29 with a modest move of +0.31% over the past week, supported by strong investor interest and above-average trading volumes. The company’s continued resilience in the Indian pharmaceutical sector has also contributed to sustaining confidence among domestic market participants.

Syncom Formulations delivers outstanding Q4 FY2025 results with EBITDA and net profit growth exceeding 95% year-on-year. The most recent financial disclosures reveal fourth-quarter revenue at ₹148.88 crores, a near-doubling from the previous year, driven by export momentum. Net profit grew 139% year-on-year, confirming robust fundamentals and operational efficiency. This outperformance strengthens the company’s attractiveness for investors focused on Indian growth opportunities.

Syncom Formulations successfully commissions a 435 KWp solar power plant at its Pithampur facility, reducing long-term operational costs. The solar plant, operational since June 2025, will generate 5.65 lakh units annually, directly supporting ESG initiatives and cost optimization at the flagship manufacturing unit. Such initiatives align with evolving sustainability standards and are positively perceived by both local analysts and institutional investors.

Syncom Formulations maintains a leading position in export markets with 86% of sales now from international clients. In the past week, corporate communications have emphasized the group’s presence in nearly 25 countries and recognition for over 400 registered products. This export strength shields revenue from local market volatility and enhances the brand’s profile within the highly competitive Indian pharmaceutical sector.

The trading window remains closed until 48 hours after announcement of Q1 FY2026 results, reinforcing transparency and regulatory compliance. The company’s strict adherence to SEBI regulations ensures a fair and orderly market, increasing confidence among professional investors and reinforcing the credibility of Syncom Formulations among India-based market participants.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.